Tazarotene (topical)
تازاروتن (موضعی)
🧴 DermatologicalsTopical retinoid
Market / country: 🇺🇸 USA
Tazorac (US)
🧮 Dose calculator
Psoriasis and steroid-responsive dermatoses · Regimen source: FDA Tazorac cream · 2.2
🛡️ Safety & information
Contraindications
- ⛔ Pregnancy; hypersensitivity to any component. FDA Tazorac cream · 4
Warnings
- • Embryofetal toxicity (negative pregnancy test and contraception); local irritation; photosensitivity and sunburn. FDA Tazorac cream · 5
Formulations
- Cream 0.05% and 0.1% — cream 🇺🇸 USA FDA Tazorac cream · 3
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA Tazorac cream · 4
“TAZORAC Cream is contraindicated in: Pregnancy.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Tazorac cream · 8.2
“Risk Summary There is no information regarding the presence of tazarotene in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tazorac cream · 8.4
“The safety and efficacy of TAZORAC Cream have not been established in patients with psoriasis under the age of 18 years, or in patients with acne under the age of 12 years.”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Tazorac cream · 8.5
“No overall differences in safety or effectiveness were observed between these subjects and younger subjects.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Tazorac cream · 8.3
“Contraception Females Based on animal studies, TAZORAC Cream may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )].”
🔗 Reference links
- FDA (approval record)NDA021184
- DailyMed (FDA label)FDA Tazorac cream
- MedlinePlus (NIH)Tazarotene Topical
- WHO ATC/DDDD05AX05
- Darooyab (Iran)Tazarotene-Topical
🇮🇷 Registered in Iran Darooyab · G-2333/Tazarotene-Topical
Dosage forms with Iranian generic codes, per Darooyab.
- 06734 · TAZAROTENE 0.05% 30G GEL · ژل تازاروتن ۰٫۰۵ درصد ۳۰ گرم
- 06740 · TAZAROTENE 0.1% 30G GEL · ژل تازاروتن ۰٫۱ درصد ۳۰ گرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Tazorac cream · 3FDA Tazorac cream · 2.2FDA Tazorac cream · 2.3FDA Tazorac cream · 4FDA Tazorac cream · 5FDA Tazorac cream · 8.2FDA Tazorac cream · 8.4FDA Tazorac cream · 8.5FDA Tazorac cream · 8.3FDA Tazorac cream · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-2333/Tazarotene-Topical
- Clinical review⚠ Unverified